Ruptured hepatoblastoma successfully treated with cisplatin monochemotherapy: A case report

Yang, Tianyou; Tan, Tianbao; Yang, Jiliang; Pan, Jing; Hu, Chao; Li, Jiahao; Xu, Tao; Zou, Yan

doi:10.3892/mco.2018.1643

Cited by 7 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TACE could be an option for patients who fail to respond to neoadjuvant chemotherapy. Furthermore, TACE is particularly useful for patients who experience tumour rupture [18]. Currently, neoadjuvant chemotherapy is considered the first choice for the preoperative management of hepatoblastoma.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: a retrospective analysis

et al. 2020

BMC Pediatr

Self Cite

View full text Add to dashboard Cite

Background: To report the outcomes of hepatoblastoma resected in our institution. Methods: We diagnosed 135 children with hepatoblastoma at our institution between January 2010 and December 2017. Patients who underwent liver resection were included for analysis. However, patients who abandoned treatment after diagnosis were excluded from analysis, but their clinical characteristics were provided in the supplementary material. Results: Forty-two patients abandoned treatment, whereas 93 patients underwent liver resection and were included for statistical analysis. Thirty-six, 23, 3, and 31 patients had PRETEXT stages II, III, IV, and unspecified tumours, respectively. Seven patients had ruptured tumour; 9 had lung metastasis (one patient had portal vein thrombosis concurrently). Sixteen patients underwent primary liver resection; 22, 25, and 30 patients received cisplatin-based neoadjuvant chemotherapy and delayed surgery, preoperative transarterial chemoembolization (TACE) and delayed surgery, and a combination of cisplatin-based neoadjuvant chemotherapy, TACE, and delayed surgery, respectively. Forty patients had both PRETEXT and POST-TEXT information available for analysis. Twelve patients were down-staged after preoperative treatment, including 2, 8, and 2 patients from stages IV to III, III to II, and II to I, respectively. Ten patients with unspecified PRETEXT stage were confirmed to have POST-TEXT stages II (n = 8) and I (n = 2) tumours. Seven tumours were associated with positive surgical margins, and 12 patients had microvascular involvement. During a median follow-up period of 30.5 months, 84 patients survived without relapse, 9 experienced tumour recurrence, and 4 died. The 2-year event-free survival (EFS) and overall survival (OS) rates were 89.4 ± 3.4%, and 95.2 ± 2.4%, respectively; they were significantly better among patients without metastasis (no metastasis vs metastasis: EFS, 93.5 ± 3.7% vs 46.7 ± 19.0%, adjusted p = 0.002. OS, 97.6 ± 2.4% vs 61.0 ± 18.1%, adjusted p = 0.005), and similar among patients treated with different preoperative strategies (chemotherapy only vs TACE only vs Both: EFS, 94.7 ± 5.1% vs 91.7 ± 5.6% vs 85.6 ± 6.7%, p = 0.542. OS, 94.1 ± 5.7% vs 95.7 ± 4.3% vs 96.7 ± 3.3%, p = 0.845).

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: a retrospective analysis

et al. 2020

BMC Pediatr

Self Cite

View full text Add to dashboard Cite

show abstract

“…TACE could be an option for patients who fail to respond to neoadjuvant chemotherapy. Furthermore, TACE is particularly useful for patients who experience tumour rupture (17). Currently, neoadjuvant chemotherapy is considered the first choice for the preoperative management of hepatoblastoma.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: A retrospective analysis

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Objective: To report the outcomes of hepatoblastoma resected in our institution. Methods: We diagnosed 135 children with hepatoblastoma at our institution between January 2010 and December 2017. Patients who underwent liver resection were included for analysis. However, patients who abandoned treatment after diagnosis were excluded from analysis, but their clinical characteristics were provided in the supplementary material. Results: Forty-two patients abandoned treatment, whereas 93 patients underwent liver resection and were included for statistical analysis. Thirty-six, 23, 3, and 31 patients had PRETEXT stages II, III, IV, and unspecified tumours, respectively. Seven patients had ruptured tumour; 9 had lung metastasis (one patient had portal vein thrombosis concurrently). Sixteen patients underwent primary liver resection; 22, 25, and 30 patients received cisplatin-based neoadjuvant chemotherapy and delayed surgery, preoperative transarterial chemoembolization (TACE) and delayed surgery, and a combination of cisplatin-based neoadjuvant chemotherapy, TACE, and delayed surgery, respectively. Forty patients had both PRETEXT and POST-TEXT information available for analysis. Twelve patients were down-staged after preoperative treatment, including 2, 8, and 2 patients from stages IV to III, III to II, and II to I, respectively. Ten patients with unspecified PRETEXT stage were confirmed to have POST-TEXT stages II (n=8) and I (n=2) tumours. Seven tumours were associated with positive surgical margins, and 12 patients had microvascular involvement. During a median follow-up period of 30.5 months, 84 patients survived without relapse, 9 experienced tumour recurrence, and 4 died. The 2-year event-free survival (EFS) and overall survival (OS) rates were 89.4±3.4%, and 95.2±2.4%, respectively; they were significantly better among patients without metastasis (no metastasis vs metastasis: EFS, 93.5±3.7% vs 46.7±19.0%, adjusted p =0.004. OS, 97.6±2.4% vs 61.0±18.1%, adjusted p =0.003), and similar among patients treated with different preoperative strategies (chemotherapy only vs TACE only vs Both: EFS, 94.7±5.1% vs 91.7±5.6% vs 85.6±6.7%, p =0.542. OS, 94.1±5.7% vs 95.7±4.3% vs 96.7±3.3%, p =0.845). Conclusion: The OS for patients with hepatoblastoma who underwent liver resection was satisfactory. Neoadjuvant chemotherapy and TACE seemed to have a similar effect on OS. However, the abandonment of treatment by patients with hepatoblastoma was common, and may have biased our results.

show abstract

“…TACE could be an option for patients who fail to respond to neoadjuvant chemotherapy. Furthermore, TACE is particularly useful for patients who experience tumour rupture [15].…”

Section: Discussionmentioning

confidence: 99%

Outcomes of children with hepatoblastoma managed at a tertiary hospital in China

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Objective: To summarise our experiences in hepatoblastoma management in South ChinaMethods: We diagnosed 135 children with hepatoblastoma at our institution between January 2010 and December 2017. Information regarding demographics, clinical data, and outcomes were retrospectively collected and analysed. Results: Ninety-three patients underwent liver resection and were enrolled in this study. Thirty-six, 23, 3, and 31 patients had PRETEXT stages II, III, IV, and unspecified tumours, respectively. Seven patients had ruptured tumour, 9 had lung metastasis, and 1 had portal vein thrombosis. Sixteen patients underwent primary liver resection, 22 received neoadjuvant chemotherapy and delayed surgery, 25 received preoperative transarterial chemoembolisation and delayed surgery, and 30 received a combination of neoadjuvant chemotherapy, transarterial chemoembolisation, and delayed surgery. Forty patients had both PRETEXT and POST-TEXT information available for analysis. Twelve cases were downstaged after preoperative treatment: 2 from stage IV to III, 8 from stage III to II, and 2 from stage II to I. Ten patients with unspecified PRETEXT stage were confirmed to have POST-TEXT stages II (n=8) and I (n=2) tumours. The PRETEXT and POST-TEXT stages were significantly different. Seven tumours were associated with positive surgical margins, and 12 patients had microvascular involvement. During a median follow-up period of 30.5 months, 84 patients survived without relapse, 9 experienced tumour recurrence, and 4 died. The two-year EFS and OS rates were significantly better among patients without metastasis. The two-year EFS and OS rates were similar among patients treated with different preoperative strategies.Conclusion: The outcomes of hepatoblastoma after resection were excellent.

show abstract

Ruptured hepatoblastoma successfully treated with cisplatin monochemotherapy: A case report

Cited by 7 publications

References 8 publications

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: a retrospective analysis

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: a retrospective analysis

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: A retrospective analysis

Outcomes of children with hepatoblastoma managed at a tertiary hospital in China

Contact Info

Product

Resources

About